{"id":"W3019339134","doi":"10.1093/rheumatology/keaa111.274","title":"P281 52-Week efficacy and safety of ixekizumab in r-axSpA/AS patients naïve to biologic treatments or with prior inadequate response/intolerance to tumor necrosis factor inhibitors","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ankylosing spondylitis; Internal medicine; Placebo; Etanercept; Gastroenterology; Tumor necrosis factor alpha; Physical therapy; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001512359,0.0006988598,0.002085435,0.0002975176,0.0002895551,0.0005719202,0.0003833671,0.0007652004,0.00279435],"category_scores_gemma":[0.001503491,0.0003108792,0.0009011358,0.0002178439,0.0004252355,0.0006308865,0.0003006186,0.001331758,0.0004895899],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003008595,"about_ca_system_score_gemma":0.000514041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003133737,"about_ca_topic_score_gemma":0.0004210341,"domain_scores_codex":[0.9992809,0.0003038543,0.00007289117,0.0001677987,0.00007349601,0.0001011266],"domain_scores_gemma":[0.9988843,0.0002561808,0.0003277283,0.00007219834,0.00008703154,0.0003726438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8962613,0.01331843,0.009462818,0.0008168314,0.0007108611,0.000189753,0.0001226222,0.0009482049,0.02629502,0.00005517467,0.0009798682,0.05083904],"study_design_scores_gemma":[0.2168371,0.7084651,0.0640001,0.00007115756,0.0009120597,0.0003009631,0.00008936511,0.001591941,0.005873361,0.0001246844,0.001683787,0.00005032093],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973027,0.00154582,0.0001258028,0.00006397751,0.00003693086,0.0002167876,0.0002815424,0.00001900334,0.0004074251],"genre_scores_gemma":[0.9977241,0.0003806364,0.0002264271,0.0000947299,0.00005558701,0.0003528167,0.0003870097,0.000005539336,0.000773049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00279435,"threshold_uncertainty_score":0.009348035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02274999506459234,"score_gpt":0.2689245563101915,"score_spread":0.2461745612455992,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}